Stockscreener 앱 받기
77.58
0.33%
-0.26
전일 마감가:
$77.84
열려 있는:
$77.545
하루 거래량:
10.90M
Relative Volume:
0.69
시가총액:
$194.81B
수익:
$63.92B
순이익/손실:
$17.43B
주가수익비율:
11.29
EPS:
6.87
순현금흐름:
$17.04B
1주 성능:
+2.00%
1개월 성능:
-1.47%
6개월 성능:
-21.78%
1년 성능:
-40.82%
1일 변동 폭
$77.08
$77.90
1주일 범위
$75.69
$79.18
52주 변동 폭
$73.31
$134.63
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
MRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
77.58 | 190.99B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
713.71 | 679.94B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
152.94 | 364.11B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
183.26 | 325.05B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
112.75 | 216.45B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
67.35 | 286.02B | 43.59B | 15.04B | 10.74B | 3.3766 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Merck Issues Statement On Potential Reduced Dosing Recommendation For Gardasil 9 - marketscreener.com
Merck: Dividend Near A 12-Year High, But I Won't BuyHere's Why (NYSE:MRK) - Seeking Alpha
Merck: Defensive Yield Meets Long-Term Optionality - Seeking Alpha
Merck (MRK) Advises Against Changing Gardasil Dosing Schedule - GuruFocus
Merck contends single dosing of Gardasil vaccine should be avoided - Seeking Alpha
Merck (MRK) Stands Firm on Gardasil 9 Dosing Standards | MRK Stock News - GuruFocus
Merck: Undervalued In Light Of Key Risks (NYSE:MRK) - Seeking Alpha
Merck & Co. Stock: Inventory Doesn’t Lie (NYSE:MRK) - Seeking Alpha
July 3rd Options Now Available For Merck (MRK) - Nasdaq
3 Deep-Value Stocks to Buy as Bulls Take a Breather - Investing.com
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference - BioSpace
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Merck and imec to develop a disruptive MicroPhysiological Systems platform - New Electronics
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Merck (NYSE:MRK) Collaborates With Antengene For Promising Cancer Therapy Evaluation - Yahoo Finance
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab) - BioSpace
Chloramine B Market to Witness Massive Growth by 2032 | Merck & Co., Inc., Anhui BBCA Pharmaceuticals Co., Ltd - openPR.com
Merck & Co., Inc.'s (NYSE:MRK) CEO Will Probably Find It Hard To See A Huge Raise This Year - simplywall.st
Berenberg Adjusts Price Target on Merck & Co. to $100 From $115, Maintains Buy Rating - marketscreener.com
Merck Announces Collaboration With Imec To Develop Disruptive Microphysiological Systems Platform - marketscreener.com
UBS maintains Buy on Merck stock, reiterates $105 target By Investing.com - Investing.com India
MRK November 21st Options Begin Trading - Nasdaq
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
UBS maintains Buy on Merck stock, reiterates $105 target - Investing.com
Merck: Phase 3 trial begins in esophageal cancer - marketscreener.com
CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com India
Breakthrough Cancer Drug Enters Phase 3 Trial: Merck Targets Deadly Esophageal Cancer with 15% Survival Rate - Stock Titan
Merck: progress report in hypertension (PAH) - marketscreener.com
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - BioSpace
Merck to Present New Clinical and Outcomes Research Data at The - GuruFocus
Merck's WINREVAIR Shows Promising Long-Term Safety Profile in Largest PAH Clinical Trial Analysis Yet - Stock Titan
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer - Clinical Trials Arena
[Pfizer Inc, AstraZeneca, Merck & Co. Inc] Breakthroughs In Bladder Cancer Treatment Market Research 2025 - openPR.com
Merck & Co., Inc. (NYSE:MRK) Earns “Neutral” Rating from Citigroup - Defense World
Traders Buy Large Volume of Put Options on Merck & Co., Inc. (NYSE:MRK) - Defense World
Merck Continues to Deliver Growth in Turbulent Times - chemeurope.com
Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers - insights.citeline.com
Decoding Merck & Co's Options Activity: What's the Big Picture? - Nasdaq
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With KeytrudaMerck & Co (NYSE:MRK) - Benzinga
Why Merck & Co., Inc. (MRK) Is Among the Best Cheap Stocks to Buy Now for Beginners - Insider Monkey
Merck & Co., Inc. (MRK): One of the Best Dividend Growth Stocks with High Yields - Insider Monkey
Jefferies not seeing significant impact to Merck, Bristol from draft guidance - Yahoo Finance
Merck brings another big business to small town De Soto - NewsBreak: Local News & Alerts
Merck's (MRK) Keytruda Hits Milestone in Ovarian Cancer Trial - GuruFocus
Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer - MSN
Merck (MRK) Achieves Key Milestones in Ovarian Cancer Trial with KEYTRUDA | MRK Stock News - GuruFocus
Merck stock rises as Keytruda succeeds in ovarian cancer (MRK) - Seeking Alpha
Merck’s Keytruda shows promise in ovarian cancer trial - Investing.com
The Zacks Analyst Blog Highlights Oracle, IBM, Merck and Earth Science Tech - Yahoo Finance
Merck secures FDA approval for Welireg to treat advanced PPGL - World Pharmaceutical Frontiers
13 Best Cheap Stocks to Invest in for Beginners - Insider Monkey
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.22%
자본화:
|
볼륨(24시간):